Replimune's New Equity Incentive Awards
Replimune Group, Inc. (NASDAQ: REPL), a forward-thinking biotechnology company focused on developing cutting-edge oncolytic immunotherapies, has recently made exciting strides in expanding its team. The Woburn, Massachusetts-based company announced the issuance of inducement equity awards aimed at newly hired non-executive employees. This strategic move is designed to enhance the company’s innovative edge in the competitive biopharmaceutical market.
Details of the Inducement Awards
In total, Replimune granted equity awards to 53 new employees as an incentive to join their dynamic team. These awards comprise non-qualified stock options allowing for the purchase of an aggregate of 98,450 shares of the company's stock. Additionally, there are restricted stock units representing an aggregate of 155,875 shares. The stock option grant is priced at $7.49 per share, mirroring the closing price on the date the awards were granted. Each option comes with a generous 10-year term and a vesting schedule spread over four years, providing 25% vesting at the one-year mark and gradual monthly vesting thereafter for the rest of the term.
Grant Process and Compliance
These inducement awards have been formally approved by Replimune's compensation committee and adhere to the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While these awards fall outside of the company's 2018 Equity Incentive Plan, their terms align with the existing plan, ensuring consistency in employee benefits.
About Replimune Group, Inc.
Founded in 2015, Replimune is dedicated to transforming cancer treatment methodologies through pioneering innovation. The company’s proprietary RPx platform stands out with its robust HSV-1 backbone, designed to amplify immunogenic cell death and stimulate a robust anti-tumor immune response. The RPx platform's unique ability to induce both local and systemic activities allows for effective direct targeting of tumors while simultaneously modifying the surrounding tumor microenvironment. This comprehensive approach sets the stage for synergistic applications with both established and experimental treatment options.
Commitment to Innovation
As part of its commitment to pioneering advancements in cancer therapies, Replimune seeks to explore the versatility of its oncolytic immunotherapies in various treatment scenarios. This adaptability may enhance the effectiveness of existing cancer treatments, providing new hope for patients facing challenging diagnoses. By adding experienced professionals through these inducement awards, Replimune aims to bolster its innovative capabilities and further develop its promising pipeline.
Investor Relations and Media Contacts
Replimune remains committed to transparency and maintaining a robust relationship with its investors and the public. Investor inquiries can be directed to Chris Brinzey at ICR Westwicke at 339.970.2843. For media relations, Arleen Goldenberg can be contacted at 917.548.1582.
For additional information on Replimune’s research, pipeline, and company developments, please visit www.replimune.com.
Frequently Asked Questions
What are the recent inducement awards granted by Replimune?
Replimune granted equity awards to 53 new non-executive employees as an incentive for their employment.
What does the equity award consist of?
The awards include non-qualified stock options for 98,450 shares and 155,875 restricted stock units.
What is the vesting schedule for these stock options?
The options will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly thereafter.
What is Replimune's mission?
Replimune aims to transform cancer treatment through innovative oncolytic immunotherapies, focusing on enhancing systemic immune responses.
Who can be contacted for investor inquiries?
Investors can reach out to Chris Brinzey at ICR Westwicke for any inquiries regarding the company.
